2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1992

Trends In Outpatient Treatment Of Gout In The US: From 1993 To 2009
Abstract Number: 101

Trends In Prescription Of Opioids From 2003-2009 In Persons With Knee Osteoarthritis
Abstract Number: 1078

Trends In Prevalence Of Knee Pain Among US Adults, National Health Interview Survey 2002-2010
Abstract Number: 616

Trends Of Mortality Associated To Systemic Lupus Erythematosus At The Nation Level: A Multiple Cause-Of-Death Analysis In France
Abstract Number: 2894

Triggering Receptor Expressed on Myeloid Cells 1 In Systemic Lupus Erythematosus
Abstract Number: 2216

Tubastatin A, a Selective Histone Deacetylase-6 Inhibitor, Suppresses Synovial Inflammation and Joint Destruction In a Collagen Antibody-Induced Arthritis Mouse Model
Abstract Number: 1138

Tuberculin Skin Test and Booster Phenomenon In a Rheumatoid Arthritis Population. Differences Between Early and Established Disease
Abstract Number: 1371

Tuberculosis Infection In Patients With Tumor Necrosis Factor–α Antagonists In South Korea;retrospective Analysis Using By National Health Insurance Review and Assessment Service
Abstract Number: 2224

Tumor Necrosis Factor Alpha Induces Anti-Citrullinated Protein Antibodies and Arthritis In Part Through Peptidyl Arginine Deiminase 4
Abstract Number: 776

Tumor Necrosis Factor Alpha Modifies Chromatin Landscape and Amplifies Inflammatory Responses To Subsequent Stimuli In Synovial Fibroblasts
Abstract Number: 804

Tumour Necrosis Factor Inhibitors and The Risk Of Acute Coronary Syndrome In Rheumatoid Arthritis – a National Cohort Study
Abstract Number: 99

Twenty-First Century Prevalence Of Frequent Knee Pain, Radiographic, Symptomatic and Clinical Knee Osteoarthritis According to American College Of Rheumatology Criteria In Southern Sweden
Abstract Number: 2704

Twist1 Regulates Transforming Growth Factor Beta Dependent Activation Of Fibroblasts In Fibrosis
Abstract Number: 1202

Two Family Kindreds With Blau’s Syndrome Associated With Unusual NOD2 Mutations
Abstract Number: 1607

Two Year Follow-Up On Biologics Use In 13 Centers- Data From The International Registry For Biologics In Systemic Lupus Erythematosus

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].